Head And Neck Cancer (HNC) Market Report 2026

Head And Neck Cancer (HNC) Market Overview

• Head And Neck Cancer (HNC) market size has reached to $2.16 billion in 2025 • Expected to grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rising Cigarette Smoking Fuels Growth In Market • Market Trend: Advancements In Immuno-Oncology Drugs With Targeted Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Head And Neck Cancer (HNC) Market?

Head and neck cancer (HNC) refers to a group of epithelial malignancies arising in the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, and salivary glands. The majority are squamous cell carcinomas, with risk factors including tobacco, alcohol, and human papillomavirus (HPV) infection. The main types of head and neck cancer (HNC) are laryngeal cancer, pharyngeal cancer, salivary gland cancer, lip & oral cavity cancer, nasopharyngeal cancer, and others. Laryngeal cancer develops in the larynx, commonly known as the voice box, which is responsible for producing sound and aiding in breathing and swallowing. The different treatments include chemotherapy, surgery, radiation therapy, targeted therapy, and others. The various diagnosis are bioscopy screening tests, blood tests, dental diagnosis, imaging, and endoscopy and are distributed through various distribution channels such as hospitals pharmacies, retail pharmacies, and e-commerce and used by various end users such as hospital, specialty clinics, ambulatory surgical centers, and others.

What Is The Head And Neck Cancer (HNC) Market Growth Forecast?

The head and neck cancer (hnc) market size is expected to see strong growth in the next few years. It will grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing investments in precision oncology research, rising demand for minimally invasive treatments, expansion of immunotherapy pipelines, growing use of AI-assisted diagnostics, increasing focus on personalized cancer care. Major trends in the forecast period include increasing adoption of targeted and immunotherapy treatments, rising use of advanced diagnostic imaging techniques, growing focus on early cancer detection, expansion of multimodal treatment approaches, enhanced integration of precision oncology.

Global Head And Neck Cancer (HNC) Market Segmentation

1) By Type: Laryngeal Cancer, Pharyngeal Cancer, Salivary Gland Cancer, Lip And Oral Cavity Cancer, Nasopharyngeal Cancer 2) By Treatment: Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Other Treatments 3) By Diagnosis: Bioscopy Screening Tests, Dental Diagnosis, Imaging, Endoscopy 4) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies 5) By End User: Hospital, Specialty Clinics Subsegments: 1) By Laryngeal Cancer: Supraglottic Laryngeal Cancer, Glottic Laryngeal Cancer, Subglottic Laryngeal Cancer 2) By Pharyngeal Cancer: Oropharyngeal Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer 3) By Salivary Gland Cancer: Parotid Gland Cancer, Sublingual Gland Cancer, Submandibular Gland Cancer, Minor Salivary Gland Cancer 4) By Lip And Oral Cavity Cancer: Lip Cancer, Buccal Mucosa Cancer, Tongue Cancer, Gingival Cancer, Palate Cancer 5) By Nasopharyngeal Cancer: Early-Stage Nasopharyngeal Cancer, Advanced-Stage Nasopharyngeal Cancer

What Is The Driver Of The Head And Neck Cancer (HNC) Market?

The increasing incidences of cigarette smoking is expected to propel the growth of the head and neck cancer (HNC) market going forward. Cigarette smoking is the act of inhaling and exhaling smoke from burning tobacco contained in cigarettes, often associated with health risks and addiction. The increasing cigarette smoking incidence is often driven by factors such as stress, social influences, aggressive marketing, and accessibility of tobacco products. Head and neck cancer drugs help mitigate the harmful effects of cigarette smoking by targeting smoking-induced molecular alterations and treating cancers linked to tobacco use, while also emphasizing the need to reduce exposure to smoking-related carcinogens for better treatment outcomes. For instance, in October 2024, according to the European Respiratory Society (ERS), a Switzerland-based non-profit organization, a study covering smoking trends among young people revealed a significant rise in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the increased incidence of cigarette smoking is driving the growth of the head and neck cancer (HNC) industry.

Key Players In The Global Head And Neck Cancer (HNC) Market

Major companies operating in the head and neck cancer (hnc) market are Pfizer Inc., Siemens Healthcare Private Limited, F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Healthcare AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Koninklijke Philips N.V., Boehringer Ingelheim, Fresenius Kabi AG, Incyte Corporation, Exelixis Inc., Astellas Pharma Inc., Rakuten Medical Inc., Merus N.V.

Global Head And Neck Cancer (HNC) Market Trends and Insights

Major companies operating in the head and neck cancer (HNC) market are focusing on developing innovative formulations such as immune oncology drugs, to enhance treatment efficacy, improve patient survival rates, and address unmet medical needs in managing complex and advanced-stage cancers. Immuno-oncology drugs refer to treatments that harness the body's immune system to recognize and fight cancer cells. These therapies include checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. For instance, in November 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched toripalimab, an immune oncology drug for adults with a rare form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. This drug is designed for treating recurrent or metastatic nasopharyngeal carcinoma. It will be marketed under the name Zytorvi. The drug has demonstrated a 48% reduction in the risk of progression or death when used in combination with standard chemotherapy (gemcitabine and cisplatin).

What Are Latest Mergers And Acquisitions In The Head And Neck Cancer (HNC) Market?

In September 2023, Coherus BioSciences, a US-based biopharmaceutical company, acquired Surface Oncology Inc. (SURF) for an undisclosed amount. With this acquisition, Coherus BioSciences aimed to enhance its immuno-oncology portfolio by integrating Surface Oncology's promising drug candidates, including SRF114 and SRF388, which are being developed to target various cancers, including head and neck cancer, thereby advancing Coherus' position in the competitive oncology market and potentially expanding its therapeutic offerings in immunotherapy treatments. Surface Oncology Inc. (SURF) is a US-based clinical-stage immuno-oncology company that engages in the development of cancer therapies.

Regional Outlook

North America was the largest region in the head and neck cancer (HNC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Head And Neck Cancer (HNC) Market?

The head and neck cancer (HNC) market consists of revenues earned by providing services such as systemic therapy, photodynamic therapy (PDT) and combined modality therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The head and neck cancer (HNC) market also includes sales of targeted therapy drugs, and combination therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Head And Neck Cancer (HNC) Market Report 2026?

The head and neck cancer (hnc) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer (hnc) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.